Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Total Non-Current Liabilities (2018 - 2025)

10x Genomics (TXG) has disclosed Total Non-Current Liabilities for 8 consecutive years, with $238.6 million as the latest value for Q4 2025.

  • Quarterly Total Non-Current Liabilities rose 17.25% to $238.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $238.6 million through Dec 2025, up 17.25% year-over-year, with the annual reading at $238.6 million for FY2025, 17.25% up from the prior year.
  • Total Non-Current Liabilities hit $238.6 million in Q4 2025 for 10x Genomics, up from $235.8 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $238.6 million in Q4 2025 to a low of $181.9 million in Q3 2021.
  • Historically, Total Non-Current Liabilities has averaged $203.5 million across 5 years, with a median of $200.8 million in 2024.
  • Biggest five-year swings in Total Non-Current Liabilities: decreased 14.75% in 2021 and later increased 18.01% in 2022.
  • Year by year, Total Non-Current Liabilities stood at $193.0 million in 2021, then grew by 14.11% to $220.3 million in 2022, then decreased by 0.2% to $219.8 million in 2023, then decreased by 7.44% to $203.5 million in 2024, then grew by 17.25% to $238.6 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for TXG at $238.6 million in Q4 2025, $235.8 million in Q3 2025, and $200.6 million in Q2 2025.